Journal
RHEUMATOLOGY
Volume 48, Issue 7, Pages 734-740Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kep091
Keywords
Systemic sclerosis; Adhesion molecules; Junctional adhesion molecules; VCAM-1; ICAM-1
Categories
Funding
- National Institute of Health [AI-40987, AR-48267]
- Office of Research and Development
- Medical Research Service, Department of Veterans Affairs
- Scleroderma Research Foundation
- NIH General Clinical Research Center [M01-RR-00042, UL1-RR024986]
Ask authors/readers for more resources
Methods. The expression of JAM-B, JAM-C, CD99, ICAM-1 and VCAM-1 in SSc skin was determined by immunohistology and cell surface ELISA. Myeloid U937 cellSSc dermal fibroblast adhesion assays or in situ adhesion assays to SSc skin were performed. Results. JAM-C and CD99 expression on endothelial cells (ECs) in SSc skin was decreased compared with expression on normal ECs. CD99 was overexpressed on mononuclear cells in SSc skin and on SSc dermal fibroblasts. Neutralizing ICAM-1 inhibited the binding of U937 cells to SSc dermal fibroblasts. In addition, blocking both ICAM-1 and VCAM-1 inhibited U937 cell adhesion to either proximal (less involved) or distal (more involved) SSc skin. Conclusions. These studies show that JAM-C and CD99 are aberrantly expressed in SSc skin. However, these adhesion molecules do not mediate myeloid cellSSc skin adhesion. In contrast, we demonstrate an important role for ICAM-1 and VCAM-1 in the retention of myeloid cells in SSc skin, suggesting that targeting these molecules may be useful SSc therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available